Dr. Bekaii-Saab on Expanding Landscape in CRC

Tanios Bekaii-Saab, MD
Published: Wednesday, Mar 01, 2017



Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

The armamentarium in CRC is expanding; moreover, agents across multiple lines of therapy are becoming available for patients and, overall, improving their survival, Bekaii-Saab explains. It is very important to understand sequencing of therapies, he adds. This is a major question currently among the CRC community.

In the second-line setting, there are 2 agents available: regorafenib (Stivarga) and TAS-102. The optimal sequence of these agents in the second-line setting is still unknown, he adds.
SELECTED
LANGUAGE


Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

The armamentarium in CRC is expanding; moreover, agents across multiple lines of therapy are becoming available for patients and, overall, improving their survival, Bekaii-Saab explains. It is very important to understand sequencing of therapies, he adds. This is a major question currently among the CRC community.

In the second-line setting, there are 2 agents available: regorafenib (Stivarga) and TAS-102. The optimal sequence of these agents in the second-line setting is still unknown, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x